ArticleOncoimmunology2014
Trial Watch: Immunostimulatory monoclonal antibodies in cancer therapy.
Article in Oncoimmunology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 79 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
79 citing papers in PubMed, 112 citations in OpenAlex.
- Inhibition of KDEL Receptors Remodels the Tumor Microenvironment for T Cell Independent Tumor Regression.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- The multiple functions of CD5 in diseases related to immune disorders.Annals of medicine · 2025Review
- Updates on radiotherapy-immunotherapy combinations: Proceedings of 8th Annual ImmunoRad Conference.Oncoimmunology · 2025Article
- Transforming cancer immunotherapy: integration of distinct immune-based approaches as redefined dual immunotherapy with potential third-sensitizer.Experimental hematology & oncology · 2025Review
- Article
- Frequencies of an Immunogenic HER-2/International journal of molecular sciences · 2023Article
- Autoantibodies - enemies, and/or potential allies?Frontiers in immunology · 2022Review
- Trial Watch: combination of tyrosine kinase inhibitors (TKIs) and immunotherapy.Oncoimmunology · 2022Review
- Nanoparticle-based approaches to target the lymphatic system for antitumor treatment.Cellular and molecular life sciences : CMLS · 2021Review
- Article
- Article
- The Role of Immunotherapy in the Treatment of Adrenocortical Carcinoma.Biomedicines · 2021Review
- Local Destruction of Tumors and Systemic Immune Effects.Frontiers in oncology · 2021Review
- Chimeric antigen receptor-engineered natural killer cells for cancer immunotherapy.Journal of hematology & oncology · 2020Review
- Detection of immunogenic cell death and its relevance for cancer therapy.Cell death & disease · 2020Review
- Influence of antigen density and immunosuppressive factors on tumor-targeted costimulation with antibody-fusion proteins and bispecific antibody-mediated T cell response.Cancer immunology, immunotherapy : CII · 2020Article
- Trial watch: STING agonists in cancer therapy.Oncoimmunology · 2020Review
- Trial watch: TLR3 agonists in cancer therapy.Oncoimmunology · 2020Review
- Engineering nanoparticles to reprogram radiotherapy and immunotherapy: recent advances and future challenges.Journal of nanobiotechnology · 2020Review
- Future of cancer immunotherapy using plant virus-based nanoparticles.Future science OA · 2019Review
19 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immunostimulatory monoclonal antibodies (mAbs) exert antineoplastic effects by eliciting a novel or reinstating a pre-existing antitumor immune response. Most often, immunostimulatory mAbs activate T lymphocytes or natural killer (NK) cells by inhibiting immunosuppressive receptors, such as cytotoxic T lymphocyte-associated protein 4 (CTLA4) or programmed cell death 1 (PDCD1, best known as PD-1), or by engaging co-stimulatory receptors, like CD40, tumor necrosis factor receptor superfamily, member 4 (TNFRSF4, best known as OX40) or TNFRSF18 (best known as GITR). The CTLA4-targeting mAb ipilimumab has been approved by the US Food and Drug Administration for use in patients with unresectable or metastatic melanoma in 2011. The therapeutic profile of ipilimumab other CTLA4-blocking mAbs, such as tremelimumab, is currently being assessed in subjects affected by a large panel of solid neoplasms. In the last few years, promising clinical results have also been obtained with nivolumab, a PD-1-targeting mAb formerly known as BMS-936558. Accordingly, the safety and efficacy of nivolumab and other PD-1-blocking molecules are being actively investigated. Finally, various clinical trials are underway to test the therapeutic potential of OX40- and GITR-activating mAbs. Here, we summarize recent findings on the therapeutic profile of immunostimulatory mAbs and discuss clinical trials that have been launched in the last 14 months to assess the therapeutic profile of these immunotherapeutic agents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.